- €14.52m
- €10.72m
- €13.19m
Brief: Biofrontera Q1 Revenue Down At About EUR 5.6 Mln
Brief: Biofrontera Submits Application For FDA Approval Of New BF-RhodoLED XL Lamp
Brief: Biofrontera Closes Capital Raise With Gross Proceeds Of EUR 24.7 Mln
Brief: Biofrontera Submits Study Report Of Pharmacokinetics Study To FDA
Brief: Biofrontera Submits Study Report Of Pharmacokinetics Study To FDA
Brief: Biofrontera Announces Gross Proceeds Of EUR 24.7 Million
Brief: Biofrontera AG Announces Pricing Of US$8.9 Mln Firm Commitment Public Offering Of American Depositary Shares
Brief: Biofrontera Appoints Ludwig Lutter As New CFO
Brief: Biofrontera Preliminary FY Revenue At EUR 30.3-30.6 Mln
Brief: Biofrontera Says Cologne Higher Regional Court Grants Approval Of Capital Increase
Brief: Biofrontera AG Says Unit, Galenica AB Signed Exclusive License & Supply Agreement For Marketing Of Ameluz, BF-RhodoLED
Brief: Biofrontera Enters Into License And Supply Agreement With Galenica AB
Brief: Biofrontera Resolves Mandatory Conversion Of Subordinated Mandatory Convertible Bonds
Brief: Biofrontera Q3 Revenue Eur 4.7 Mln
Brief: Biofrontera 9-Month Loss Before Income Tax Widens To EUR 11.6 Million
Brief: Biofrontera Receives Statement From German Federal Court Of Justice
Brief: Biofrontera AG Says In Q3 Generated Between EUR 2.7 And 2.9 Mln From Sales Of Ameluz In USA
Brief: Biofrontera Preliminary Unaudited 9M Revenue At About EUR 20.8 To 21.0 Mln
Brief: Biofrontera Reports Completion Of Clinical Phase Of Pharmacokinetics Study